GLP1R and GIPR Dual-Target Drugs in Humanized GIPR Mice
Multi-target drugs targeting GLP1R/GIPR/GCGR have demonstrated superior efficacy for weight loss and glycemic control compared to single-target GLP1R drugs. However,...
Continue Reading
Multi-target drugs targeting GLP1R/GIPR/GCGR have demonstrated superior efficacy for weight loss and glycemic control compared to single-target GLP1R drugs. However,...
Continue Reading
Integrating drug targets, molecular types, and clinical translation Introduction: Metabolic dysfunction-associated steatohepatitis (MASH), a growing global health concern, has garnered...
Continue Reading
Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity,...
Continue Reading
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a serious liver disease. If left untreated, MASH can...
Continue Reading
Diabetic neuropathy, a common complication of diabetes, affects approximately 50% of diabetic patients and can lead to a range of...
Continue Reading
Diabetic retinopathy is a major contributor to vision loss and blindness in working-age adults with diabetes. Developing animal models that...
Continue Reading
Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development...
Continue Reading
Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across...
Continue Reading
Studies have demonstrated that obesity can promote cancer progression through mechanisms that include chronic low-grade inflammation. Previous research with diet-induced...
Continue Reading